Regulatory
Key facts
FDA approved Rasonque (daraxonrasib)
Key facts
Rasonque is described as a RAS inhibitor
Key facts
The approval is for adults with metastatic pancreatic adenocarcinoma
Atlas Watchline
The FDA said it approved Rasonque, also known as daraxonrasib, for adults with metastatic pancreatic adenocarcinoma.